All In Biotech

Drug Trial Radar · NCT06905327

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered QCZ484 in Healthy Subjects and Subjects With Mild Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Mar 8, 2023

Primary completion

Sep 25, 2024

Study completion Jul 1, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.

Conditions

  • Mild Hypertension

Interventions

  • QCZ484Drug

    doses of 50, 150, 300 or 600 mg via subcutaneous injection

  • PlaceboDrug

    via subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events (AEs)Time frame: Part A: up to 12 weeks post dose. Part B: up to 8 weeks post dose.
  2. Number of participants with abnormalities in any laboratory parameterTime frame: Part A: up to 12 weeks post dose. Part B: up to 8 weeks post dose

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Adelaide, Australia

  • Novartis Investigative Site

    Herston, Queensland, Australia

  • Novartis Investigative Site

    Morayfield, Queensland, Australia

  • Novartis Investigative Site

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.